FDA panel advises calcitonin salmon not be used for osteoporosis

(Reuters) – A panel of advisers to the Food and Drug Administration recommended on Tuesday that the agency no longer support the marketing of calcitonin salmon as a treatment for osteoporosis in post-menopausal women. The panel voted 12-9 that the benefit of calcitonin salmon products in treating bone-thinning associated with osteoporosis is outweighed by a potential increase in the risk of cancer. Calcitonin salmon is a man-made version of the hormone calcitonin that is found in salmon. …